[Pleurodesis in malignant pleural effusion: bleomycin vs. mitoxantrone]

Area of Science:

• Oncology
• Pulmonology
• Clinical Pharmacology

Background:

• Malignant pleural effusion is a common complication of various cancers, significantly impacting patient quality of life.
• Pleurodesis is a standard procedure to manage malignant pleural effusion, aiming to prevent fluid re-accumulation.
• Bleomycin (BMC) and mitoxantrone (MIT) are chemotherapeutic agents used for pleurodesis, with varying efficacy and safety profiles.

Purpose of the Study:

• To compare the therapeutic efficacy and safety of bleomycin (BMC) versus mitoxantrone (MIT) for pleurodesis in patients with malignant pleural effusion.
• To evaluate remission rates and adverse events associated with BMC and MIT pleurodesis via chest tube.

Main Methods:

• A controlled clinical trial involving 102 patients with malignant pleural effusion from various cancers.
• Patients were randomized to receive pleurodesis via chest tube using either bleomycin (BMC, n=49) or mitoxantrone (MIT, n=47).
• Efficacy was assessed by remission rates (complete and partial) at 30 and 90 days post-procedure; adverse events were also recorded.

Main Results:

• Bleomycin (BMC) pleurodesis achieved significantly higher remission rates compared to mitoxantrone (MIT) at both 30 days (91% vs 73%, p < 0.05) and 90 days (83% vs 61%, p < 0.05).
• Complete remission rates were higher with BMC (51% at 30 days, 40% at 90 days) versus MIT (35% at 30 days, 29% at 90 days).
• No statistically significant differences in adverse events were observed between the BMC and MIT groups.

Conclusions:

• Bleomycin (BMC) is a safe and effective sclerosing agent for pleurodesis via chest tube in malignant pleural effusion.
• BMC demonstrates superior therapeutic efficacy in achieving effusion remission compared to mitoxantrone (MIT).
• The comparable safety profiles suggest BMC as a preferred option for pleurodesis in this patient population.